Literature DB >> 15728287

Prioritizing interventions to improve rates of thrombolysis for ischemic stroke.

.   

Abstract

BACKGROUND: Thrombolytic treatment has been shown to be effective in the treatment of ischemic stroke when initiated within 3 hours of symptom onset, yet few patients receive thrombolytics.
OBJECTIVE: To estimate expected increases in use of thrombolytics for ischemic stroke given the following interventions: educating patients to present earlier, optimizing Emergency Medical Services (EMS) response/transport times, optimizing hospital systems, and extending the treatment window.
METHODS: As part of a Centers for Disease Control-sponsored Coverdell Acute Stroke Pilot Registry, the authors prospectively identified all patients with an initial diagnosis of ischemic stroke at 11 hospitals in California over a 3-month period. Timing of symptom onset, EMS response, hospital arrival, treatment, and reasons for nontreatment were evaluated, and hypothetical treatment rates for thrombolysis for interventions on the stroke-care continuum were derived based on observed rates of eligibility and treatment.
RESULTS: Of 374 patients with ischemic stroke, 88 (23.5%) arrived at the emergency department within 3 hours of symptom onset, of whom 16 (4.3%) received thrombolysis. If all patients with known onset times had called 911 immediately, the expected overall rate of thrombolytic treatment within 3 hours would have increased from 4.3 to 28.6%. Expected rates of thrombolysis were lower for other interventions: instantaneous prehospital response 5.5%, perfect hospital care 11.5%, and extension of time window to 6 hours 8.3%. If all patients with known onset had arrived within 1 hour and been optimally treated, 57% could have been treated.
CONCLUSION: Campaigns that educate patients to seek treatment sooner should be major components of system-wide interventions to increase rates of thrombolysis for acute ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728287     DOI: 10.1212/01.WNL.0000151850.39648.51

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  74 in total

1.  Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.

Authors:  Opeolu Adeoye; Richard Hornung; Pooja Khatri; Dawn Kleindorfer
Journal:  Stroke       Date:  2011-06-02       Impact factor: 7.914

2.  Thymosin beta4: a candidate for treatment of stroke?

Authors:  Daniel C Morris; Michael Chopp; Li Zhang; Zheng G Zhang
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

3.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

4.  Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke.

Authors:  D C Morris; M Chopp; L Zhang; M Lu; Z G Zhang
Journal:  Neuroscience       Date:  2010-08-25       Impact factor: 3.590

5.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

6.  Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results.

Authors:  Thomas M Hemmen; Rema Raman; Kama Z Guluma; Brett C Meyer; Joao A Gomes; Salvador Cruz-Flores; Christine A Wijman; Karen S Rapp; James C Grotta; Patrick D Lyden
Journal:  Stroke       Date:  2010-08-19       Impact factor: 7.914

7.  Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke.

Authors:  Hagen Kunte; Sein Schmidt; Michael Eliasziw; Gregory J del Zoppo; J Marc Simard; Florian Masuhr; Markus Weih; Ulrich Dirnagl
Journal:  Stroke       Date:  2007-08-02       Impact factor: 7.914

8.  Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.

Authors:  Natalia S Rost; Eric E Smith; Muhammad A Pervez; Philip Mello; Paul Dreyer; Lee H Schwamm
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-04-24

Review 9.  Rationale for a nanomedicine approach to thrombolytic therapy.

Authors:  Gregory M Lanza; Jon N Marsh; Grace Hu; Michael J Scott; Anne H Schmieder; Shelton D Caruthers; Dipanjan Pan; Samuel A Wickline
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 10.  The effects of estrogen in ischemic stroke.

Authors:  Edward C Koellhoffer; Louise D McCullough
Journal:  Transl Stroke Res       Date:  2012-12-07       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.